Código QR (código de barras bidimensional)

A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer

Abstract Background The addition of the cyclin dependent kinase inhibitor (CDKi) dinaciclib to Poly-(ADP-ribose) polymerase inhibitor (PARPi) therapy is a strategy to overcome resistance to PARPi in tumors that exhibit homologous recombination (HR) deficiencies as well as to expand PARPi therapy to...

תיאור מלא

שמור ב:
Principais autores: Paige Baldwin, Shicheng Yang, Adrienne Orriols, Sherrie Wang, Needa Brown, Srinivas Sridhar
פורמט: Artigo
שפה:Inglês
יצא לאור: BMC 2024-03-01
סדרה:Cancer Nanotechnology
נושאים:
Nano-cocktail
Talazoparib
Dinaciclib
PARP inhibitor
CDK inhibitor
Triple-negative breast cancer
גישה מקוונת:https://doi.org/10.1186/s12645-023-00240-4
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים